Pharsight

Drugs that contain Tasimelteon

1. Hetlioz patents expiration

HETLIOZ Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5856529 VANDA PHARMS INC Benzofuran and dihydrobenzofuran melatonergic agents
Dec, 2022

(1 year, 2 months ago)

US11760740 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US11566011 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US10829465 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US10071977 VANDA PHARMS INC Highly purifid pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11633377 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9539234 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9855241 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

USRE46604 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10149829 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9060995 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10449176 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10945988 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10610510 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10980770 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9549913 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11285129 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11850229 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11833130 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9730910 VANDA PHARMS INC Treatment of circadian rhythm disorders
May, 2034

(10 years from now)

US11786502 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US10610511 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US11141400 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US10376487 VANDA PHARMS INC Method of treatment
Jul, 2035

(11 years from now)

US10179119 VANDA PHARMS INC Method of treatment
Aug, 2035

(11 years from now)

US11266622 VANDA PHARMS INC Method of treatment
Aug, 2035

(11 years from now)

US11759446 VANDA PHARMS INC Liquid tasimelteon formulations and methods of use thereof
Feb, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 1, 2027

Market Authorisation Date: 31 January, 2014

Treatment: Treatment of non-24 hour sleep-wake disorder by administering tasimelteon; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon; Treatment of non-24-hour sl...

Dosage: CAPSULE;ORAL

How can I launch a generic of HETLIOZ before it's drug patent expiration?
More Information on Dosage

HETLIOZ family patents

Family Patents

2. Hetlioz Lq patents expiration

HETLIOZ LQ Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5856529 VANDA PHARMS INC Benzofuran and dihydrobenzofuran melatonergic agents
Dec, 2022

(1 year, 2 months ago)

US11760740 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US10829465 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US10071977 VANDA PHARMS INC Highly purifid pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US11566011 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11633377 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11285129 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10980770 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10149829 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9539234 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10610510 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11833130 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11850229 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9730910 VANDA PHARMS INC Treatment of circadian rhythm disorders
May, 2034

(10 years from now)

US11141400 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US11786502 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US10610511 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US10376487 VANDA PHARMS INC Method of treatment
Jul, 2035

(11 years from now)

US10179119 VANDA PHARMS INC Method of treatment
Aug, 2035

(11 years from now)

US11266622 VANDA PHARMS INC Method of treatment
Aug, 2035

(11 years from now)

US11202770 VANDA PHARMS INC Liquid tasimelteon formulations and methods of use thereof
Dec, 2040

(16 years from now)

US11759446 VANDA PHARMS INC Liquid tasimelteon formulations and methods of use thereof
Feb, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 1, 2027

Market Authorisation Date: 01 December, 2020

Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of ...

Dosage: SUSPENSION;ORAL

More Information on Dosage

HETLIOZ LQ family patents

Family Patents